(MENAFN- GlobeNewsWire - Nasdaq) The global CMO/CDMO biotechnology market offers significant opportunities driven by the rise of biologics and biosimilars. Key prospects include the surge in outsourcing for cost efficiency, capacity expansion, and strategic partnerships. Mid-sized firms and regions like the U.S. and South Korea show strong growth potential.

Dublin, Oct. 08, 2025 (GLOBE NEWSWIRE) -- The "CMO/CDMO Biotechnology Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)" report has been added to ResearchAndMarkets's offering.
The global CMO/CDMO biotechnology market is poised for substantial growth, driven by the increasing reliance on contract manufacturing and development services in the biopharmaceutical industry. With growing demand for cost-effective, scalable, and high-quality manufacturing solutions, the market is projected to rise from US$ 14.0 Bn in 2025 to US$ 32.0 Bn by 2032, progressing at a CAGR of 12.54% during the forecast period.
Contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) are playing a vital role in supporting biotechnology and biopharmaceutical companies in their drug development and production cycles. These organizations offer a wide spectrum of services, including cell-line development, bio-manufacturing, analytical testing, clinical supply, fill-finish, and packaging. As pharmaceutical companies look to streamline operations and accelerate time-to-market, outsourcing to CDMOs has become a strategic imperative.
Key Market Drivers
One of the primary growth drivers for the CMO/CDMO biotechnology market is the increasing focus on novel biologics and biosimilars. The demand for large-scale production of monoclonal antibodies, gene therapies, and recombinant proteins is propelling the need for technologically advanced and flexible contract manufacturing services. Additionally, the emergence of innovative expression systems and disposable bioreactor technologies is enhancing productivity and reducing manufacturing costs.
A rising number of biologics approvals and biosimilar launches in major markets such as the U.S. and Europe are also boosting market demand. Manufacturers are investing in capacity expansion and integrated services to serve the growing complexity and volume of biologic therapeutics. Moreover, regulatory support and the need for faster commercialization are reinforcing the trend of outsourcing drug development and manufacturing.
Business Opportunities
The expansion of biosimilar pipelines, coupled with the adoption of single-use technologies and intensified regulatory support, creates vast opportunities for market players. Companies are increasingly forming strategic partnerships and acquisitions to expand capabilities. For instance, AGC Biologics' acquisition of Molecular Medicine S.p.A. expanded its end-to-end cell and gene therapy offerings. Similarly, Lonza's development of the GSv9T platform enhanced its recombinant protein manufacturing capabilities.
The mid-sized CMO/CDMO segment, offering extensive and specialized services, continues to gain traction due to its operational flexibility and growing expertise. Furthermore, the ongoing evolution of the CDMO model-focusing on integrated solutions from discovery to commercial-scale production-opens new avenues for long-term partnerships.
Regional Analysis
The U.S. remains the dominant market in North America, supported by a strong pharmaceutical manufacturing base, high merger and acquisition activity, and rapid adoption of single-use bioreactor systems. High investment in biologics production facilities and technological advancements in biomanufacturing are solidifying the region's leadership.
In Europe, the U.K. stands out as a lucrative market with a growing number of CDMOs offering end-to-end biopharmaceutical solutions, particularly for gene and cell therapy. Manufacturers in this region focus on high-quality service offerings with a global presence.
Asia Pacific, particularly South Korea, is emerging as a key market due to its robust development services and strategic investments by global CDMOs. South Korean players like Samsung Biologics are significantly expanding cell-line development platforms and bioreactor capacities, contributing to regional market growth.
Key Players

These companies are focusing on enhancing their service portfolios, expanding geographically, and embracing strategic collaborations to address increasing global demand for biologic development and production services.

Several key players are leading market expansion through innovation and capacity enhancement, including:

• Patheon N.V.
• Catalent
• Samsung Biologics Co., Ltd
• Lonza
• Boehringer Ingelheim
• AGC Biologics, Inc.
• WuXi Biologics
• AbbVie Inc.
• Avid Bioservices, Inc.
• Fujifilm Diosynth Biotechnologies
• Rentschler Biopharma SE
• KBI Biopharma (JSR Corporation)
• Cytovance Biologics
• Xpress Biologic

Market Segmentation

By Service

• Stand-alone Services
• Integrated Services

By Product

• Monoclonal Antibodies
• Recombinant Proteins
• Vaccines
• Others

By Expression System

• Mammalian
• Microbial
• Others

By Company Size

• Small
• Mid-sized
• Large

By Scale of Operations

• Clinical
• Commercial

By Region

• North America
• Latin America
• Europe
• East Asia
• South Asia & Pacific
• Middle East & Africa

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN08102025004107003653ID1110167170